CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status
Last Updated: Friday, July 17, 2026
An overview of clinical applications, toxicity profiles, and future directions for CDK4/6 inhibitors. This analysis reviews data on palbociclib, ribociclib, and abemaciclib from trials such as PALOMA-1,2,3; MONALEESA-1,2,3,7; MONARCH-1,2,3; MonarchE; and NATALEE.